Communiqués VolitionRx Limited

Actions

VNRX

US9286612067

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 16:35:30 27/07/2026			Varia. 5j.	Varia. 1 janv.
0,9060 ^USD	-9,40%		-18,19%	-81,92%

07/07	VolitionRx Limited publie des données démontrant la valeur pronostique du test Nu.Q Cancer chez les patients atteints d'un cancer du poumon nouvellement diagnostiqué	CI
17/06	VolitionRx Limited et Sysmex Corporation annoncent une collaboration pour optimiser le test Nu.Q NETs H3.1 sur la plateforme Sysmex	CI

Communiqués

07/07	VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test	PR
17/06	VolitionRx Announces Collaboration with Sysmex	PR
08/06	VolitionRx Announces Pricing of $4.6 Million Public Offering	PR
03/06	VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring	PR
28/05	VolitionRx : Short Corporate Deck, May 2026	PU
28/05	VolitionRx : Corporate Presentation May 2026	PU
27/05	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets	PR
15/05	VolitionRx : Short Corporate Deck, May 2026	PU
15/05	VolitionRx : Corporate Presentation May 2026	PU
15/05	VolitionRX: Q1 Earnings Snapshot	AQ
14/05	VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update	PR
11/05	VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update	PR
06/05	VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats	PR
29/04	Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing	PR
23/04	VolitionRx Announces Acceptance of Compliance Plan by NYSE American	PR
20/04	Volition Launches rNuQ™ Webshop Broadening Product Range	PR
01/04	VolitionRx : Short Corporate Deck, Apr 2026	PU
01/04	VolitionRx : Corporate Presentation April 2026	PU
01/04	VolitionRX: Q4 Earnings Snapshot	AQ
31/03	VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update	PR
31/03	VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium	PR
26/03	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference	PR
25/03	VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update	PR
25/03	Volition Announces Detection of Over 95% of Early-Stage Cancers	PR
18/03	Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA	PR